Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture

Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells

(2013) Sven Schnichels et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Ranibizumab injection for diabetic macular edema: meta-analysis of systemic safety and systematic review

(2013) Marwan A. Abouammoh   CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE

Inhibition of ocular neovascularization by a novel peptide derived from human placenta growth factor-1

(2012) Ying Zheng et al.   ACTA OPHTHALMOLOGICA

Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences

(2012) Heidrun L Deissler et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?

(2012) Kleanthis Manousaridis et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Targeted deletion of Vegfa in adult mice induces vision loss

(2012) Toshihide Kurihara et al.   JOURNAL OF CLINICAL INVESTIGATION

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

(2012) Daniel F. Martin et al.   OPHTHALMOLOGY

Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

(2012) Jeffrey S. Heier et al.   OPHTHALMOLOGY

THE EFFECTS OF AFLIBERCEPT ON THE VIABILITY AND METABOLISM OF OCULAR CELLS IN VITRO

(2012) David A. Ammar et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells

(2009) Alexa Karina Klettner et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study

(2009) Alexander Rouvas et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY